Crassula Pharmaceuticals

Crassula Pharmaceuticals Launches India’s First QuanticSphere™ Drug-Delivery Technology

admin — Mon, 22 Dec 2025 02:05:27 +0000

Crassula Pharmaceuticals Launches India’s First QuanticSphere Drug-Delivery Technology

Crassula Pharmaceuticals has officially launched its proprietary QuanticSphere drug-delivery technology in India, marking a significant milestone in the advancement of pharmaceutical and nutraceutical delivery systems. The launch event, held in Indore, represents the first introduction of QuanticSphere in the Indian market and underscores Crassula’s continued focus on science-driven innovation and patient-centric formulation design.

QuanticSphere is a patented delivery platform engineered to enhance the absorption, stability, and bioavailability of active pharmaceutical ingredients and nutritional compounds. The technology utilizes nano-scale, phospholipid-based vesicles to protect active ingredients from degradation in the digestive tract while facilitating efficient systemic delivery.

Addressing Limitations of Conventional Oral Formulations

One of the longstanding challenges in oral drug and nutrient delivery is poor absorption, which can limit therapeutic effectiveness and require higher dosing. QuanticSphere is designed to address this limitation by improving ingredient transport across biological membranes, maintaining stability in the gastrointestinal environment, and supporting sustained availability in the body.

The platform has broad relevance across multiple therapeutic and wellness categories, including joint health, musculoskeletal support, cartilage integrity, post-menopausal health, and general nutritional supplementation. Its design prioritizes patient tolerability, digestive comfort, and long-term compliance.

Expert Insights Shared at the Launch

During the launch event, scientific and medical experts discussed the clinical and technical significance of the QuanticSphere platform.

Dr. Bhavana Gupta, Chief Technical Officer of Crassula Pharmaceuticals, highlighted the system’s design and performance:

“QuanticSphere is a state-of-the-art delivery system developed by Crassula Pharmaceuticals. By encapsulating active ingredients in nano-sized, phospholipid-based vesicles, the technology enhances delivery efficiency while maintaining long-term stability and patient safety.”

Orthopedic specialists attending the event emphasized the potential relevance of the technology for joint-related formulations, noting its applicability in both current therapeutic approaches and future research initiatives.

Dr. Laveleen Gupta, Chief Scientific Officer of Crassula Pharmaceuticals, addressed the broader scope of the platform:

“QuanticSphere is designed as a versatile delivery platform. Beyond nutritional and joint-health applications, ongoing research is exploring its potential role in advanced therapeutic areas and chronic disease management.”

A Platform for Future Innovation

QuanticSphere has been developed as a modular and scalable technology capable of supporting a wide range of active compounds, including vitamins, minerals, botanical extracts, and pharmaceutical agents. Crassula Pharmaceuticals plans to expand its application across multiple product lines while continuing research and development efforts to explore additional therapeutic opportunities.

With this launch, Crassula Pharmaceuticals strengthens its position as a technology-driven healthcare organization focused on advancing delivery science and improving patient outcomes through innovation, precision, and clinical relevance.

Publisher Information

Crassula Pharmaceuticals

Innovating advanced drug-delivery technologies for pharmaceutical and nutraceutical applications.

For more information, visit: https://crassulapharma.com/contact

The post Crassula Pharmaceuticals Launches India’s First QuanticSphere™ Drug-Delivery Technology appeared first on Crassula Pharmaceuticals.

Happy Diwali

admin — Tue, 21 Oct 2025 02:57:06 +0000

Happy Diwali from all of us at Crassula Pharmaceuticals.

May this Festival of Lights bring renewed energy, health, and prosperity to every home.

As we celebrate illumination in all its forms, we remain committed to advancing science and wellness—with the same spirit of clarity and purpose that Diwali inspires.

Wishing you a bright, safe, and joyous Diwali.

The post Happy Diwali appeared first on Crassula Pharmaceuticals.

Season’s Greetings from Crassula

admin — Sun, 22 Dec 2024 19:08:28 +0000

Season’s Greetings from Crassula

As we wrap up another year of delivering quality solutions and forging new horizons in the health and wellness sector, we want to express our heartfelt appreciation for our clients, partners, and community who have entrusted us with their well-being.

This holiday season, we are filled with gratitude for every milestone reached and every partnership formed. By working together, we’re forging a stronger path toward innovation and excellence—driven by our commitment to improving lives worldwide.

Thank you for being part of our journey. May your holidays be filled with peace, joy, and good health, and may the coming year bring you continued success and happiness.

Happy Holidays and a Prosperous New Year from Crassula!

The post Season’s Greetings from Crassula appeared first on Crassula Pharmaceuticals.

India Independence Day

admin — Thu, 15 Aug 2024 04:50:35 +0000

On this special day, we join in celebrating India’s 78th Independence Day, honoring the resilience, unity, and unwavering spirit of its people. As we commemorate the journey to freedom, let us continue striving for progress and prosperity. Wishing everyone a day filled with pride and reflection. Happy Independence Day!

The post India Independence Day appeared first on Crassula Pharmaceuticals.

Crassula Launches Vascutan Plus, Irbesartan/Hydrochlorothiazide, in Honduras

admin — Wed, 08 May 2024 13:58:31 +0000

Crassula Launches Vascutan Plus, Irbesartan/Hydrochlorothiazide, in Honduras

Lauren Sacks
May 8, 2024
1:58 pm
No Comments

Tegucigalpa, Honduras – Continuing its commitment to cardiovascular health, Crassula Pharmaceuticals is proud to announce the release of Vascutan Plus, a combination medication containing Irbesartan and Hydrochlorothiazide, in Honduras. This new addition enhances Crassula’s portfolio by offering a comprehensive treatment solution for hypertension.

Vascutan Plus combines Irbesartan, an angiotensin II receptor blocker (ARB), with Hydrochlorothiazide, a thiazide diuretic. This synergistic combination not only effectively lowers blood pressure by relaxing blood vessels but also helps eliminate excess salt and water from the body, further reducing blood pressure and the strain on the cardiovascular system.

“Crassula Pharmaceuticals remains at the forefront of innovation in healthcare with the launch of Vascutan Plus, aimed at providing a more effective hypertension management strategy,” stated Dr. Roopesh Gupta, CEO of Crassula Pharmaceuticals. “This advanced formula is designed to meet the diverse needs of patients dealing with high blood pressure, offering them a higher level of care and support.”

Vascutan Plus is now available throughout Honduras, signifying a key advancement in the management of hypertension and its associated risks. For more information on Vascutan Plus and other products from Crassula Pharmaceuticals, please visit www.crassulapharma.com or contact sales@crassulapharma.com.

About Crassula Pharmaceuticals

Specializing in high-quality healthcare products, Crassula Pharmaceuticals focuses on innovation, quality, and patient safety to enhance health and well-being both locally and globally. The company offers a wide range of therapeutic solutions designed to address the healthcare needs of the community.

The post Crassula Launches Vascutan Plus, Irbesartan/Hydrochlorothiazide, in Honduras appeared first on Crassula Pharmaceuticals.

Crassula Pharmaceuticals Launches Vascutan, Irbesartan, in Honduras

admin — Mon, 29 Apr 2024 19:55:10 +0000

Crassula Introduces Vascutan for Advanced Hypertension Control in Honduras

Lauren Sacks
April 29, 2024
7:55 pm
No Comments

Tegucigalpa, Honduras – Crassula Pharmaceuticals, a leader in cardiovascular healthcare solutions, is thrilled to announce the market introduction of Vascutan, an Irbesartan-based medication, in Honduras. This strategic expansion of Crassula’s cardiovascular portfolio underscores the company’s commitment to combating hypertension and associated cardiac conditions.

Irbesartan, the active ingredient in Vascutan, is a potent angiotensin II receptor blocker (ARB) that effectively lowers blood pressure by relaxing blood vessels. The introduction of Vascutan aims to provide patients with a reliable and efficient option for managing hypertension, which is a major risk factor for heart disease and stroke.

“Crassula Pharmaceuticals is dedicated to enhancing patient health through innovative and effective treatments. The launch of Vascutan demonstrates our commitment to addressing the urgent needs of hypertensive patients,” said Mr. Arturo Yidi, COO of Crassula. “We believe Vascutan will play a critical role in improving the cardiovascular health of the Honduran population.”

Vascutan is now available in Honduras, providing a new tool in the fight against high blood pressure and its complications. For more information about Vascutan and other Crassula products, please visit www.crassulapharma.com or contact sales@crassulapharma.com.

About Crassula Pharmaceuticals

Crassula specializes in high-quality healthcare products that focus on innovation, quality, and patient safety. Our mission is to improve health and well-being in Honduras and beyond, with a diverse product range that addresses various therapeutic areas and healthcare needs.

Discover the Benefits of Vascutan for Hypertension Treatment

Lowered Blood Pressure

Vascutan is a Potent Angiotensin II Receptor Blocker (ARB) that Effectively Lowers Blood Pressure

Reduced Risk of Heart Disease and Stroke

Vascutan Improves Overall Cardiovascular Health

Take Control of Your Hypertension

Manage Your Serious Health Condition with Vascutan

Peace of Mind

Choose the Best Treatment for Hypertension

Vascutan is the right choice for those seeking effective treatment for high blood pressure. With Irbesartan as its key ingredient, Vascutan is a potent Angiotensin II receptor blocker (ARB) that relaxes blood vessels and effectively manages hypertension, reducing the risk of heart disease and stroke significantly. Take control of your health today and choose Vascutan. For more information, contact us at +1 954-676-7060 or email at info@crassulapharma.com.

By clicking Learn More, you’re confirming that you agree with our Terms and Conditions.

The post Crassula Pharmaceuticals Launches Vascutan, Irbesartan, in Honduras appeared first on Crassula Pharmaceuticals.

We are proud to announce a new addition to our team at CRASSULA!

admin — Tue, 16 Apr 2024 20:16:43 +0000

We are proud to announce a new addition to our team at CRASSULA!

We are thrilled to announce an exciting new addition to our team at CRASSULA!

Please join us in welcoming Daniel Suazo as the new Medical Representative Lead at #CrassulaHonduras. Daniel comes to us with an impressive background in the healthcare sector, where he has consistently demonstrated exceptional leadership and a deep commitment to improving access to quality treatments.
In his new role, Daniel will play a crucial part in advancing our initiatives to enhance the accessibility and quality of life for patients in Honduras. We are confident that his expertise and leadership will greatly contribute to our efforts in delivering innovative and effective solutions to those in need.

Welcome aboard, Daniel! We are excited to see all the great things we will accomplish together.

#Welcome #PharmaceuticalIndustry #HealthInnovation #TeamCrassula #CrassulaHonduras

The post We are proud to announce a new addition to our team at CRASSULA! appeared first on Crassula Pharmaceuticals.

Introducing Glycedil: Revolutionizing Type 2 Diabetes Management in Honduras

admin — Tue, 26 Mar 2024 20:33:37 +0000

Introducing Glycedil: Revolutionizing Type 2 Diabetes Management in Honduras

Crassula Honduras Announces the Launch of Glycedil, Sitagliptin 100mg, in Honduras

Tegucigalpa, Honduras – In a significant expansion of its diabetes care portfolio, Crassula Pharmaceuticals proudly introduces Glycedil, a Sitagliptin 100mg tablet, to the Honduran market. This strategic launch underscores Crassula’s unwavering commitment to innovating in the field of chronic disease management and improving the quality of life for individuals living with Type 2 diabetes.

Sitagliptin, the active ingredient in Glycedil, is a highly effective dipeptidyl peptidase-4 (DPP-4) inhibitor. It works by enhancing the body’s own ability to lower blood sugar levels, especially after meals. The 100mg dosing of Glycedil is designed to optimize blood sugar control while minimizing side effects, offering a new hope for patients seeking a more balanced approach to managing their diabetes.

“Crassula Pharmaceuticals is dedicated to advancing healthcare outcomes with accessible, innovative treatments. The launch of Glycedil is a testament to our commitment to providing effective solutions for the complex challenges faced by patients with Type 2 diabetes,” said Dr. Josué Daniel Suazo, National Sales Manager at Crassula Honduras. “We are excited to offer this new therapeutic option to the people of Honduras, further enhancing our mission to make advanced care available to all.”

Glycedil is now available across Honduras, marking a pivotal step forward in the management of Type 2 diabetes. For more information on Glycedil and other Crassula products, please visit www.crassulapharma.com or contact sales@crassulapharma.com

About Crassula Honduras

Crassula Honduras is a division of Crassula LLC., a USA based company at the forefront of developing high-quality healthcare products, focusing on innovation, quality, and patient safety to improve health and well-being both in Honduras and internationally. With a diverse product range that addresses a wide spectrum of therapeutic areas, Crassula is committed to meeting the healthcare needs of communities around the globe.

The post Introducing Glycedil: Revolutionizing Type 2 Diabetes Management in Honduras appeared first on Crassula Pharmaceuticals.

Crassula Launches Relixib, Etoricoxib 120mg Coated Tablet, in Honduras

admin — Sun, 24 Mar 2024 17:25:54 +0000

Crassula Launches Relixib, Etoricoxib 120mg Coated Tablet, in Honduras

Crassula Pharmaceuticals Launches Relixib, Etoricoxib 120mg, in Honduras

Tegucigalpa, Honduras – Crassula Honduras, a leading pharmaceutical manufacturer renowned for its commitment to quality, is excited to announce the introduction of Relixib, an etoricoxib 120mg tablet, to the Honduran market. This new addition to Crassula’s portfolio reinforces the company’s dedication to providing advanced healthcare solutions and addressing the needs of patients suffering from chronic pain and inflammation.

Etoricoxib, the active ingredient in Relixib, belongs to a class of medications known as selective COX-2 inhibitors, offering targeted relief from pain and swelling associated with various arthritic conditions, including osteoarthritis, rheumatoid arthritis, and gout. The 120mg dosage has been carefully selected to optimize efficacy while minimizing potential side effects, ensuring a better quality of life for patients.

“Through the launch of Relixib, Crassula Honduras underscores its ongoing commitment to enhance healthcare outcomes with innovative and accessible treatment options. Relixib exemplifies our mission to address unmet medical needs in the management of pain and inflammation,” stated Dr. Bhawana Gupta, CTO of Crassula Pharmaceuticals. “We are proud to offer this significant advancement in pain management to the people of Honduras, furthering our goal of making superior healthcare solutions readily accessible.”

Relixib is now available in Honduras, offering a new hope for patients seeking effective management of chronic pain and inflammatory conditions. For more information about Relixib and other Crassula Pharmaceuticals products, please visit www.crassulapharma.com or contact sales@crassulapharma.com.

About Crassula Honduras

Crassula Honduras is a division of Crassula Pharmaceuticals, a company synonymous with high-quality healthcare products. With a focus on innovation, quality, and patient safety, Crassula strives to improve health and well-being in Honduras and beyond. The company’s diverse product portfolio meets a wide range of healthcare needs, ensuring that patients have access to the latest advancements in medical treatment.

The post Crassula Launches Relixib, Etoricoxib 120mg Coated Tablet, in Honduras appeared first on Crassula Pharmaceuticals.

Dr. Bhavana Gupta

admin — Thu, 08 Feb 2024 22:07:27 +0000

Crassula Pharmaceuticals Welcomes

Crassula is thrilled to announce the appointment of Dr. Bhavana Gupta as its new Chief Technical Officer (CTO). Dr. Gupta will be at the forefront of managing the technical operations of the company, including overseeing the research and development department. Her role will also encompass serving as a vital technical advisor, directly reporting to Mr. Roopesh Gupta, the CEO and Founder of Crassula Pharmaceuticals.

Dr. Gupta brings to Crassula a rich background in medicine and biotechnology, holding a Ph.D. in Biotechnology. With over 17 years of research experience in Contract Research Organizations (CRO) and preclinical drug discovery within the pharmaceutical industry, Dr. Gupta’s expertise is a valuable addition to Crassula. She is renowned for her exceptional leadership in project management, customer communications, target identification and validation, and high-throughput screening (HTS).

An accomplished scientist, Dr. Gupta possesses profound knowledge in cell biology, assay development, and screening, particularly focusing on small molecules, biologics, and the discovery of natural product drugs. Her ability to skillfully balance organizational objectives with productivity and relationships has consistently enhanced competitive business edges in her previous roles.

Before joining Crassula, Dr. Gupta contributed significantly to the pharmaceutical and biotechnology fields through her roles as Assistant General Manager and Head of Cell Biology at Natco Pharmaceuticals, Senior Principal Scientist at Sapien Biosciences, and Team Lead at TCG Life Sciences. Her extensive experience spans various therapeutic areas, including pain, inflammation, immuno-oncology, and metabolic disorders, making her a pivotal figure in drug discovery.

Dr. Gupta’s appointment marks a significant milestone in Crassula’s journey towards innovation and excellence in pharmaceuticals. Her leadership and expertise are expected to drive forward the company’s mission of developing groundbreaking solutions for healthcare challenges.

About Crassula

Crassula LLC is a company dedicated to the production of pharmaceutical and nutraceutical solutions. Our presence extends internationally, manufacturing prescription drugs (Rx), nutritional supplements, and over-the-counter (OTC) pharmaceutical products. We strive to improve the health and well-being of communities through reliable, innovative, affordable, and high-quality solutions.

For further information, please contact:

Lauren Sacks
Human Resources Manager
lauren.sacks@crassulapharma.com

The post Dr. Bhavana Gupta appeared first on Crassula Pharmaceuticals.